Skip to main content
. 2021 May 8;296:100761. doi: 10.1016/j.jbc.2021.100761

Figure 4.

Figure 4

Deterioration of cardiac diastolic function by Peptide 2 administration.A–G, echocardiographic measurement of each parameter analyzed every 4 weeks during the 8-week experimental period. H, cardiac fibrosis detected by Sirius red staining after the 8-week treatment. The dotted square was enlarged and shown below. I, summary graph of the percentage of fibrotic areas in the cardiac sections. J, confocal images of CD68 immunostaining. Cell membrane and nuclei were counterstained with WGA and DAPI, respectively. K, summary graph of the number of CD68-positive cells. Scale bars: 200 μm (H) and 50 μm (J). In A–G, two-way ANOVA was applied for comparing the data between groups, and one-way ANOVA was applied for comparing the results at week 0 with those at other time points; in I and K, the data between the two groups were analyzed by Kolmogorov–Smirnov test. ∗p < 0.05 and ∗∗p < 0.01 versus Control peptide; ††p < 0.01 versus 0 week.